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Objective: Chronic Pseudomonas aeruginosa lung infection in CF patients is
characterized by persisting mucoid bioﬁlms in hypoxic endobronchial mucus.
These bioﬁlms are surrounded by numerous polymorphonuclear leukocytes (PMNs),
which are the major consumers of O2 due to production of O
−
2 . In this study, we
hypothesized that nitric oxide (NO) is also produced by the NO synthases (NOS)
in the O2-consuming PMNs in the endobronchial mucus.
Methods and Results: This hypothesis was tested on fresh expectorated sputum
from chronically infected CF patients by quantifying and visualizing the NO
production. A positive correlation was observed between the concentration of PMNs
and stable endproducts of NO production in CF sputum; NO−3 (p< 0.04, r: 0.66,
n = 10) and NO−2 (p< 0.006, r: 0.78, n = 11) using the Griess Reagent System,
indicating a production of NO by PMNs. PMNs stained with the NO-indicator,
DAF-FM, could be identiﬁed by ﬂuorescence microscopy. In addition, microsensor
analysis revealed the presence of discrete occurrences of NO. To further verify NO
production by active NOS in the PMNs, we are presently estimating O2 consumption
and DAF-FM ﬂuorescence during inhibition of NOS in CF sputum.
Conclusions: The present study suggests that besides consumption of O2 for
production of reactive oxygen species, the PMNs in CF sputum can also consume
O2 for reactive nitrogen species, i.e. NO.
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Purpose: Aspergillus precipitins aid diagnosis and monitor treatment of aspergillo-
sis. Phadia’s ImmunoCAP® ﬂuorescent immunoenzyme assay (FIEA) is a new fast,
automated method to detect IgG antibodies to Aspergillus fumigatus. This assay has
not been validated in individual patient groups and the clinical signiﬁcance of levels
is not known. This study aimed to compare the ImmunoCAP® IgG with Aspergillus
precipitins in patients with cystic ﬁbrosis (CF).
Method: Serum from 100 adult CF patients was analyzed by the ImmunoCAP®
assay for speciﬁc IgG A. fumigatus, and by counterimmunoelectrophoresis for
A. fumigatus precipitating antibodies. Phadia recommends an ImmunoCAP® result
>40mg/L as positive. The precipitin titre was recorded. For clinical analysis,
patients were grouped into those with ABPA (2003 consensus criteria), sensitisation
( class 2 speciﬁc IgE to A. fumigatus) and controls (no evidence of sensitisation).
Results: There was 50% concordance between a positive IgG result and a positive
precipitin result. Non concordance in 38% was due to a positive IgG but negative
precipitin. A ROC curve, with an area under the curve of 0.593, demonstrated that
raising the cut-off level for a positive IgG result did not improve concordance.
There was no correlation between IgG level and precipitin titre (r = 0.199). Neither
precipitin titre nor IgG level correlated with disease group. There was no signiﬁcant
difference in the mean IgG between controls and ABPA patients (p = 0.154).
Conclusion: In CF there is little correlation between the ImmunoCAP® assay and
precipitating antibodies. Neither the precipitin test nor the ImmunoCAP® IgG is a
good predictor of disease in CF.
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The UK CF Trust recommends the routine measurement of serum Igs as part of the
Annual Review. We assessed the usefulness of these tests in our clinic population.
The Annual Screen results from the preceding 12 months of our adult CF patients
(n = 253) were reviewed. All patients who had a full Ig panel (IgG, IgA, IgM
and serum electrophoresis) with contemporaneous white cell count were included.
189 patients (75%) had a complete Ig panel available for analysis. The results are
shown in Table 1.
Table 1
IgG IgA IgM
Normal 159 (84%) 106 (56%) 134 (71%)
Reduced 4 (2%) 8 (4%) 33 (17%)
reduced >10% 1 (0.5%) 7 (3.7%) 23 (12%)
Raised 26 (14%) 75 (40%) 22 (12%)
raised >10% 9 (5%) 66 (35%) 20 (11%)
20 patients had a polyclonal increase on electrophoresis, but no monoclonal bands
were seen. A raised IgA correlated well with a raised white cell count (WCC)
(r = 0.175, p = 0.02), but there was no signiﬁcant correlation between raised WCC
and IgG or IgM.Only one patient had a reduction in more than one Ig class, and
this did not have a clinical effect.
Abnormal Ig results are often seen in the CF Annual Review. Many of these are
likely to be due to an acute phase response in patients who are exacerbating.
Signiﬁcant immunodeﬁciency has not been identiﬁed by the Annual Screen process,
and no signiﬁcant management alterations have been made as a result of routinely
measuring Ig levels. An Ig panel plus electrophoresis costs £18.19 per test.
Routine measurement of Igs as part of the CF Annual Review is not indicated. By
discontinuing this, we can save up to £4600 (€5155) per year.
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Objectives: Recurrent respiratory infections trigger the chronic inﬂammatory pro-
cess in cystic ﬁbrosis (CF). The immune response to chronic Pseudomonas aerugi-
nosa lung infection in CF is predominantly of the Th2 type. The aim of this study is
to determine the long-term (6 months) effects of montelukast and azithromycin and
the effect of systemic antibiotics for 3 weeks during acute pulmonary exacerbations
on Th1/Th2 cytokine levels in children with CF prospectively.
Material and Methods: CF patients (n = 29) (8.66±3.55 years) were chosen
as study group and patients with non-CF bronchiechtasis (n = 10) (12.71±2.92
years) as control group. Study group received montelukast (n = 12), azithromycin
(n = 9) for 6 months as prophylaxis and systemic antibiotics for acute respiratory
exacerbations (n = 8) for 21 days. The Th1/Th2 cytokines (IL-2, IL-4, IL-5, TNF-a,
IFN-g, IL-10) were measured by Cytometric Bead Array (BD Biosciences, USA)
on ﬂow cytometry in serum of all patients and in sputum of patients with acute
respiratory exacerbations.
Results: The montelukast and azithromycin prophylaxis during 6 months period
prevented the acute respiratory exacerbations, increased the Shwachman Clinical
Scores without adverse effect were observed. There were no statistically signiﬁcant
differences in pre- and post-treatment cytokine levels in serum samples of CF pa-
tients who received montelukast or azithromycin for prophylaxis and in sputum
samples of CF patients with exacerbations.
Conclusion: In spite of no statistically signiﬁcant differences in serum and sputum
Th1/Th2 cytokine levels, montelukast and azithromycin for prophylaxis and sytemic
antibiotics for treatment cause clinical improvement in CF children.
